When does liraglutide patent expiry occur?
Liraglutide Patent Exclusivity in the United States
In the United States, liraglutide's primary market exclusivity, stemming from its New Drug Application (NDA) approval, expired on December 20, 2023 [1]. This date marked the end of the period during which the U.S. Food and Drug Administration (FDA) would not approve generic versions of the drug, provided patent and other exclusivities were also expired or expired by this date.
Liraglutide's Patent Landscape and Litigation
While the NDA exclusivity expired in late 2023, liraglutide's patent protection has been subject to extensive litigation [2]. DrugPatentWatch.com tracks these patent challenges, which can impact the actual market entry of generic competitors [2]. For instance, a patent related to the drug's formulation was set to expire in 2024, but this date was previously invalidated by court rulings [2].
Will Generics Enter the Market After Patent Expiry?
The entry of generic liraglutide into the U.S. market depends on the outcome of ongoing patent disputes and the expiration of all relevant exclusivities [2]. Although the NDA exclusivity ended in December 2023, further legal developments could influence the timeline for generic approvals and availability [2].
What is liraglutide used for?
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist prescribed for managing type 2 diabetes and chronic weight management [3]. It helps improve glycemic control and can lead to significant weight loss in individuals with obesity or overweight conditions and at least one weight-related comorbidity [3].
Who manufactures liraglutide?
Novo Nordisk is the pharmaceutical company that developed and markets liraglutide under brand names such as Victoza for diabetes and Saxenda for weight management [3].
Sources:
[1] https://www.drugpatentwatch.com/drug/liraglutide/us
[2] https://www.drugpatentwatch.com/drug/liraglutide/patent-expiry
[3] https://www.drugpatentwatch.com/drug/liraglutide